Hippo pathway in mammary gland development and breast cancer

Acta Biochimica et Biophysica Sinica

Volumn 47, Issue 1, 2014, Pages 53-59

  Shi, Peiguo ^a,b   Feng, Jing ^c   Chen, Ceshi ^a  

^a INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

breast cancer; Hippo pathway; mammary gland development; TAZ; YAP

Indexed keywords

HIPPO PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

ANIMAL; APOPTOSIS; BIOLOGICAL MODEL; BREAST TUMOR; CANCER STEM CELL; CARCINOGENESIS; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GROWTH, DEVELOPMENT AND AGING; HOMEOSTASIS; HUMAN; MAMMARY GLAND; METABOLISM; ORGAN SIZE; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CARCINOGENESIS; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEOSTASIS; HUMANS; MAMMARY GLANDS, HUMAN; MODELS, BIOLOGICAL; NEOPLASTIC STEM CELLS; ORGAN SIZE; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION;

EID: 84922434091     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmu114     Document Type: Review

References (108)

1. Justice RW, Zilian O, Woods DF, Noll M, Bryant PJ. The Drosophila tumor suppressor gene warts encodes a homolog of human myotonic dystrophy kinase and is required for th e control of cell shape and proliferation. Genes Dev 1995, 9: 534-546.
2. Xu T, Wang W, Zhang S, Stewart RA, Yu W. Identifying tumor suppressors in genetic mosaics: The Drosophila lats gene e ncodes a putative protein kinase. Development 1995, 121: 1053-1063.
3. Pan D. The Hippo signaling pathway in development and cancer. Dev Cell 2010, 19: 491-505.
4. Callus BA Verhagen AM Vaux DL. Association of mammalian sterile twenty kinases, Mst1 and Mst2, with hSalvador via C-terminal coiled-coil domains, leads to its stabilization and phosphorylation FEBS J 2006 273 4264-4276.
5. Praskova M, Xia F, Avruch J. MOBKL1A/MOBKL1B phosphorylation by MST1 and MST2 inhibits cell proliferation. Curr Biol 2008, 18: 311-321.
6. Hori T, Takaori-Kondo A, Kamikubo Y, Uchiyama T. Molecular cloning of a novel human protein kinase, kpm, that is homologous to warts/lats, a Drosophila tumor suppressor. Oncogene 2000, 19: 3101-3109.
7. Chan EH, Nousiainen M, Chalamalasetty RB, Schafer A, Nigg EA, Sillje HH. The Ste20-like kinase Mst2 activates the human large tumor suppressor kinase Lats1. Oncogene 2005, 24: 2076-20 86.
8. Gumbiner BM, Kim NG. The Hippo-YAP signaling pathway and contact inhibition of growth. J Cell Sci 2014, 127: 709-717.
9. Zhao B,Wei X, LiW, Udan RS, Yang Q, Kim J, Xie J, et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 2007, 21: 2747-2761.
10. Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, Cordenonsi M, Zanconato F, et al. Role of YAP/TAZ in mechanotransduction. Nature 2011, 474: 179-183.
11. Mohseni M, Sun J, Lau A, Curtis S, Goldsmith J, Fox VL, Wei C, et al. A genetic screen identifies an LKB1-MARK signalling axis controlling the Hippo-YAP pathway. Nat Cell Biol 2014, 16: 108-117.
12. Yu FX, Zhao B, Panup inthu N, Jewell JL, Lian I, Wang LH, Zhao J, et al. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell 2012, 150: 780-791.
13. Fan R, Kim NG, Gumbi ner BM. Regulation of Hippo pathway by mitogenic growth factors via phosphoinositide 3-kinase and phosphoinositidedependent kinase-1. Proc Natl Acad Sci USA 2013, 110: 2569-2574.
14. Tumaneng K, Schlege lmilch K, Russell RC, Yimlamai D, Basnet H, Mahadevan N, Fitamant J, et al. YAP mediates crosstalk between the Hippo and PI(3)K-TOR pathways by suppressing PTEN via miR-29. Nat Cell Biol 2012, 14: 13 22-1329.
15. Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA, Gayyed MF, et al. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 2007, 130: 1120-1133.
16. Hao Y, Chun A, Cheung K, Rashidi B, Yang X. Tumor suppressor LATS1 is a negative regulator of oncogene YAP. J Biol Chem 2008, 283: 5496-5509.
17. Oka T , Mazack V, Sudol M. Mst2 and Lats kinases regulate apoptotic function of Yes kinase-associated protein (YAP). J Biol Chem 2008, 283: 27534-27546.
18. Lei QY, Zhang H, Zhao B, Zha ZY, Bai F, Pei XH, Zhao S, et al. TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Mol Cell Biol 2008, 28: 2426-2436.
19. Kanai F, Marignani PA, Sarbassova D, Yagi R, Hall RA, Donowitz M, Hisaminato A, et al. TAZ: A novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. Embo J 2000, 19: 6778-6791.
20. Ota M, Sasaki H. Mammalian Tead proteins regulate cell proliferation and contact inhibition as transcriptional mediators of Hippo signaling. Development 2008, 135: 4059-4069.
21. Zhao B, Ye X, Yu J, Li L, Li W, Li S, Yu J, et al. TEAD mediates YAPdependent gene induction and growth control. Genes Dev 2008, 22: 1962-1971.
22. Zhang H, Liu CY, Zha ZY, Zhao B, Yao J, Zhao S, Xiong Y, et al. TEAD transcription factors mediate the function of TAZ in cell growth and epithelial-mesenchymal transition. J Biol Chem 2009, 284: 13355-13362.
23. Varelas X, Sakuma R, Samavarchi-Tehrani P, Peerani R, Rao BM, Dembowy J, Yaffe MB, et al. TAZ controls Smad nucleocytoplasmic shuttling and regulates human embryonic stem-cell se lf-renewal. Nat Cell Biol 2008, 10: 837-848.
24. Strano S, Munarriz E, Rossi M, Castagnoli L, Shaul Y, Sacchi A, Oren M, et al. Physical interaction with Yes-associated protein en hances p73 transcriptional activity. J Biol Chem 2001, 276: 15164-15173.
25. Visser S, Yang X. Identification of LATS transcriptional targets in HeLa cells using whole human genome oligonucleotide microarray. Gene 2010, 449: 22-29.
26. Mauviel A Nallet-Staub F Varelas X. Integrating developmental signals: A Hippo in the (path)way Oncogene 2012 31 1743-1756.
27. Wang H, Du YC, Zhou XJ, Liu H, Tang SC. The dual functions of YAP-1 to promote and inhibit cell growth in human malignancy. Cancer Metastasis Rev 2014, 33: 173-181.
28. Harvey K F, Pfleger CM, Hariharan IK. The Drosophila Mst ortholog, hippo, restricts growth and cell proliferation and promotes apoptosis. Cell 2003, 114: 457-467.
29. Zhao B, Tumaneng K, Guan KL. The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal. Nat Cell Biol 2011, 13: 877-883.
30. Halder G, Johnson RL. Hippo signaling: Growth control and beyond. Development 2011, 138: 9-22.
31. Zhang L, Yue T, Jiang J. Hippo signaling pathway and organ size control. Fly 2009, 3: 68-73.
32. Lu L, Li Y, Kim SM, Bossuyt W, Liu P, Qiu Q, Wang Y, et al. Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc Natl Acad Sci USA 2010, 107 : 1437-1442.
33. Heallen T, Zhang M, Wang J, Bonilla-Claudio M, Klysik E, Johnson RL, Martin JF. Hippo pathway inhibits Wnt signaling to restrain cardiomyocyte proliferation and heart size. Science 2011, 332: 458-461.
34. Pan D. Hippo signaling in organ size control. Genes Dev 2007, 21: 886-897.
35. Chan SW, Lim CJ, Chen L, Chong YF, Huang C, Song H, Hong W. The Hippo pathway in biological control and cancer development. J Cell Physiol 2011, 226: 928-939.
36. Udan RS, Kango-Singh M, Nolo R, Tao C, Halder G. Hippo promotes proliferation arrest and apoptosis in the Salvador/Warts pathway. Nat Cell Biol 2003, 5: 914-920.
37. Lai ZC,Wei X, Shimizu T, Ramos E, Rohrbaugh M, Nikolaidis N, Ho LL, et al. Control of cell proliferation and apoptosis by mob as tumor suppressor, mats. Cell 2005, 120: 675-685. 38.
38. Wu S, Huang J, Dong J, Pan D. Hippo encodes a Ste-20 family protein kinase that restricts cell proliferation and promotes apoptosis in conjunction with salvador and warts. Cell 2003, 114: 445-45 6.
39. Pantalacci S, Tapon N, Leopold P. The Salvador partner Hippo promotes apoptosis and cell-cycle exit in Drosophila. Nat Cell Biol 2003, 5: 921-927.
40. Jia J, Zhang W , Wang B, Trinko R, Jiang J. The Drosophila Ste20 family kinase dMST functions as a tumor suppressor by restricting cell proliferation and promoting apoptosis. Genes Dev 2003, 17: 2514-2519.
41. Benhamouche S, Curto M, Saotome I, Gladden AB, Liu CH, GiovanniniM, McClatchey AI. Nf2/Merlin controls progenitor homeostasis and tumorigenesis in the liver. Genes Dev 2010, 24: 1718-1730.
42. Schlegelmilch K, Mohseni M, Kirak O, Pruszak J, Rodriguez JR, Zhou D, Kreger BT, et al. Yap1 acts downstream of alpha-catenin to control epidermal proliferation. Cell 2011, 144: 782-795.
43. Camargo FD, Gokhale S, Johnnidis JB, Fu D, Bell GW, Jaenisch R, Brummelkamp TR. YAP1 increases organ size and expands undifferentiated progenitor cells. Curr Biol 2007, 17: 2054-2060.
44. Ramos A, Camargo FD. The Hippo signaling pathway and stem cell biology. Trends Cell Biol 2012, 22: 339-346.
45. Shaw RL, Kohlmaier A, Polesello C, Veelken C, Edg ar BA, Tapon N. The Hippo pathway regulates intestinal stem cell proliferation during Drosophila adult midgut regeneration. Development 2010, 137: 4147-4158.
46. Karpowicz P, Perez J, PerrimonN . TheHippo tumor suppressor pathway regulates intestinal stem cell regeneration. Development 2010, 137: 4135-4145.
47. Lian I Kim J Okazawa H Zhao J Zhao B Yu J Chinnaiyan A et al. The role of YAP transcription coactivator in regulating stem cell self-renewal and differentiation Genes Dev 2010 24 1106-1118 .
48. Tamm C, Bower N, Anneren C. Regulation of mouse embryonic stem cell self-renewal by a Yes-YAP-TEAD2 signaling pathway downstream of LIF. J Cell Sci 2011, 124: 1136-1144.
49. Hong JH, Hwang ES, McManus MT, Amsterdam A, Tian Y, Kalmukova R, Mueller E, et al. TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. Science 2005, 309: 1074-1078.
50. Qin H, Blaschke K, Wei G, Ohi Y, Blouin L, Qi Z, Yu J, et al. Transcriptional analysis of pluripotency reveals the Hippo pathway as a barrier to reprogramming. Hum Mol Genet 2012, 21: 2054-2067.
51. Liu H, Jiang D, Chi F, Zhao B. The Hippo pathway regulates stem cell proliferation, self-renewal, and differentiation. Protein Cell 2012, 3: 291-304.
52. Co rdenonsi M, Zanconato F, Azzolin L, ForcatoM, Rosato A, Frasson C, Inui M, et al. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 2011, 147: 759-772.
53. Bartucci M, Dattilo R, Moriconi C, Pagliuca A, Mottolese M, Federici G, Benedetto AD, et al. TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells. Oncogene 2014, doi: 10.1038/onc.2014.5.
54. Matteucci E, Maroni P, Luzzati A, Perrucchini G, Bendinelli P, Desiderio MA. Bone metastatic process of breast cancer involves methylation state affecting E-cadherin expression through TAZ and WWOX nuclear effectors. Eur J Cancer 2013, 49: 231-244.
55. Johnson R, Halder G. The two faces of Hippo: Targeting the Hippo pathway for regenerative medicine and cancer treatment. Nat Rev Drug Discov 2014, 13: 63-79.
56. Zeng Q, Hong W. The emerging role of the hippo pathway in cell contact inhibition, organ size control, and cancer development in mammals. Cancer Cell 2008, 13: 188-192.
57. Barron DA, Kagey JD. The role of the Hippo pathway in human disease and tumorigenesis. Clin Transl Med 2014, 3: 25.
58. Zhao B, Li L, Lei Q, Guan KL. The Hippo-YAP pathway in organ size control and tumorigenesis: An updated version. Genes Dev 2010, 24: 862-874.
59. Harvey KF, Zhang X, Thomas DM. The Hippo pathway and human cancer. Nat Rev Cancer 2013, 13: 246-257.
60. Mo JS, Park HW, Guan KL. The Hippo signaling pathway in stem cell biology and cancer. EMBO Rep 2014, 15: 642-656.
61. Hao J, Zhang Y, Jing D, Li Y, Li J, Zhao Z. Role of Hippo signaling in cancer stem cells. J Cell Physiol 2014, 229: 266-270.
62. Zhou J. An emerging role for Hip po-YAP signaling in cardiovascular development. J Biomed Res 2014, 28: 251-254.
63. Yao M, Wang Y, Zhang P, Chen H, Xu Z, Jiao J, Yuan Z. BMP2-SMAD signaling represses the proliferat ion of embryonic neural stem cells through YAP. J Neurosci 2014, 34: 12039-12048.
64. Chen Q, Zhang N, Gray RS, Li H, Ewald AJ, Zahnow CA, Pan D. A temporal requirement for Hippo sig naling in mammary gland differentiation, growth, and tumorigenesis. Genes Dev 2014, 28: 432-437.
65. St. John MA, TaoW, Fei X, Fukumoto R, Carcangiu ML, Brownstein DG, Parlow AF, et al. Mice deficient of Lats1 develop soft-tissue sarcomas, ovarian tumours and pituitary dysfunction. Nat Genet 1999, 21: 182-186.
66. Skibinski A, Breindel JL, Prat A, Galvan P, Smith E, Rolfs A, Gupta PB, et al. The Hippo transducer TAZ interacts with the SWI/SNF complex to regulate breast epithelial lineage commitment. Cell Rep 2014, 6: 1059-1072.
67. Overholtzer M, Zhang J, Smo len GA, Muir B, Li W, Sgroi DC, Deng CX, et al. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci USA 2006, 103: 12405-12410.
68. Wang X Su L Ou Q. Yes-associated protein promotes tumour development in luminal epithelial derived breast cancer. Eur J Cancer 2012 48 1227-1234.
69. Vlug EJ, Van de Ven RA, Vermeulen JF, Bult P, Van Diest PJ, Derksen PW. Nuclear localization of the transcriptional coactivator YAP is associated with invasive lobular breast cancer. Cell Oncol 2013, 36: 375-384.
70. Kim SK, Ju ng WH, Koo JS. Yes-associated protein (YAP) is differentially expressed in tumor and stroma according to the molecular subtype of breast cancer. Int J Clin Exp Pathol 2014, 7: 3224-3234.
71. Wang Z, Wu Y, Wang H, Zhang Y, Mei L, Fang X, Zhang X, et al. Interplay of mevalonate and Hippo pathways regulates RHAMMtranscription via YAP to modulate breast cancer cell motility. Proc Natl Acad Sci USA 2014, 111: E89-E98.
72. Serrano I, McDonald PC, Lock F, Muller WJ, Dedhar S. Inactivation of the Hippo tumour suppressor pathway by integrin-linked kinase. Nat Commun 2013, 4: 2976.
73. Lamar JM, Stern P, Liu H, Schindler JW, Jiang ZG, Hynes RO. The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. Proc Natl Acad Sci USA 2012, 109: E2441-E2450.
74. Liu R, Zhou Z, Zhao D, Chen C. The induction of KLF5 transcription factor by progesterone contributes to progesterone-induced breast cancer cell proliferation and dedifferentiation. Mol Endocrinol 2011, 25: 1137-1144.
75. Liu R, Dong JT, Chen C. Role of KLF5 in hormonal signaling and breast cancer development. Vitam Horm 2013, 93: 213-225.
76. Chen C, Bhalala HV, Qiao H, Dong JT. A possible tumor suppressor role of the KLF5 transcription factor in human breast cancer. Oncogene 2002, 21: 6567-6572.
77. Zhi X, Zhao D, Zhou Z, Liu R, Chen C. YAP promotes breast cell proliferation and survival partially through stabilizing the KLF5 transcription factor. Am J Pathol 2012, 180: 2452-2461.
78. Adler JJ, Johnson DE, Heller BL, Bringman LR, Ranahan WP, Conwell MD, Sun Y, et al. Serum deprivation inhibits the transcriptional co-activator YAP and cell growth via phosphorylation of the 130-kDa isofo rm of Angiomotin by the LATS1/2 protein kinases. Proc Natl Acad Sci USA 2013, 110: 17368-17373.
79. Ranahan WP, Han Z, Smith-Kinnaman W, Nabinger SC, Heller B, Herbert BS, Chan R, et al. The adaptor protein AMOT promotes the proliferation of mammary epithelial cells via the prolonged activation of the extracellular signal-regulated kinases. Cancer Res 2011, 71: 2203-2211.
80. Moleirinho S, Chang N, Sims AH, Tilston-Lunel AM, Angus L, Steele A, Boswell V, et al. KIBRA exhibits MST-independent functional regulation of the Hippo signaling pathway in mammals. Oncogene 2013, 32: 1821-1830.
81. Chen D, Sun Y, Wei Y, Zhang P, Rezaeian AH, Teruya-Feldstein J, Gupta S, et al. LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker. Nat Med 2012, 18: 1511-1517.
82. Hergovich A. YAP-Hippo signalling downstream of leukemia inhibitory factor receptor: Implications for breast cancer. Breast Cancer Res 2012, 14: 326.
83. Hiemer SE, Szymaniak AD, Varelas X. The transcriptional regulators TAZ and YAP direct transforming growth factor beta-induced tumorigenic phenotypes in breast cancer cells. J Biol Chem 2014, 289: 1346 1-13474.
84. Jaramillo-Rodriguez Y, Cerda-Flores RM, Ruiz-Ramos R, Lopez-Marquez FC, Calderon-Garciduenas AL. YAP expression in normal and neoplastic breast tissue: An immunohistochemical study. Arch Med Res 2014, 45: 223-228.
85. Tufail R, Jorda M, Zhao W, Reis I, Nawaz Z. Loss of Yes-associated protein (YAP) expression is associated with estrogen and progesterone receptors negativity in invasive b reast carcinomas. Breast Cancer Res Treat 2012, 131: 743-750.
86. Yuan M, Tomlinson V, Lara R, Holliday D, Chelala C, Harada T, Gangeswaran R, et al. Yes-associated protein (YAP) functions as a tumor suppressor in breast. Cell Death Differ 2008, 15: 1752-1759.
87. Matallanas D, Romano D, Yee K, Meissl K, Kucerova L, Piazzolla D, Baccarini M, et al. RASSF1 A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein. Mol Cell 2007, 27: 962-975.
88. Bendinelli P, Maroni P, Matteucci E, Luzzati A, Perrucchini G, Desiderio MA. Hypoxia inducible factor-1 is activated by transcriptional co-activator with PDZ-binding motif (TAZ) versus WWdomaincontaining oxidoreductase (WWOX) in hypoxic microenvironment of bone metastasis from breast cancer. Eur J Cancer 2013, 49: 2608-2618.
89. Chan SW, Lim CJ, Loo LS, Chong YF, Huang C, HongW. TEADs mediate nuclear retention of TAZ to promote oncogenic transformation. J Biol Chem 2009, 284: 14347-14358.
90. Zhao D Zhi X Zhou Z Chen C. TAZ antagonizes the WWP1-mediated KLF5 degradation and promotes breast cell proliferation and tumorigenesis Carcinogenesis 2012 33 59-67.
91. Chan SW, Lim CJ, Guo K, Ng CP, Lee I, HunzikerW, Zeng Q, et al. A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Res 2008, 68: 2592-2598.
92. Mi W, Lin Q, Chi ldress C, Sudol M, Robishaw J, Berlot CH, Shabahang M, et al. Geranylgeranylation signals to the Hippo pathway for breast cancer cell proliferation and migration. Oncogene 2014, doi: 10.1038/onc.2014.251.
93. Yang N, Morrison CD, Liu P, Miecznikowski J, BsharaW, Han S, Zhu Q, et al. TAZ induces growth factor-independent proliferation through activation of EGFR ligand amphiregulin. Cell Cycle 2012, 11: 2922-2930.
94. Lai D, Visser-Grieve S, Yang X. Tumour suppressor genes in chemotherapeutic drug response. Biosci Rep 2012, 32: 361-374.
95. TianW, Chen J, He H, Deng Y. MicroRNAs and drug resistance of breast cancer: Basic evidence and clinical applications. Clin Transl Oncol 2013, 15: 335-342.
96. Lai D, Ho KC, Hao Y, Yang X. Taxol resistance in breas t cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF. Cancer Res 2011, 71: 2728-2738.
97. Zhao YL, Khanal P, Savage P, She YM, C yr TD, Yang XL. YAP-Induced Resistance of Cancer Cells to Antitubulin Drugs Is Modulated by a Hippo-Independent Pathway. Cancer Res 2014, 74: 4493-4503.
98. Habbig S, Bartram MP, Muller RU, Schwarz R, Andriopoulos N, Chen S, Sagmuller JG, et al. NPHP4, a cilia-associated protein, negatively regulates the Hippo pathway. J Cell Biol 2011, 193: 633-642.
99. Habbig S, Bartram M P, Sagmuller JG, Griessmann A, Franke M, Muller RU, Schwarz R, et al. The ciliopathy disease protein NPHP9 promotes nuclear delivery and activation of the oncogenic transcriptional regulator TAZ. Hum Mol Genet 2012, 21: 5528-5538.
100. Huang W, Lv X, Liu C, Zha Z, Zhang H, Jiang Y, Xiong Y, et al. The N-terminal phosphodegron targets TAZ/WWTR1 protein for SCFbeta-TrCP-dependent degradation in response to phosphatidylinositol 3-kinase inhibition. J Biol Chem 2012, 287: 26245-26253.
101. Marastoni S, Andreuzzi E, Paulitti A, Colladel R, Pellicani R, Todaro F, Schiavinato A, et al. EMILIN2 down-modulates the Wnt signalling pathway and suppresses breast cancer cell growth and migration. J Pathol 2014, 232: 391-404.
102. Alarcon C, Zaromytidou AI, Xi Q, Gao S, Yu J, Fu jisawa S, Barlas A, et al. Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGF-beta pathways. Cell 2009, 139: 757-769.
103. Zhang H, Pasolli HA, Fuchs E. Yes-associated protein (YAP) transcriptional coactivator functions in balancing growth and differentiation in skin. Proc Natl Acad Sci USA 2011, 108: 2270-2275.
104. Liu C, HuangW, Lei Q. Regulation and function of the TAZ transcription co-activator. Int J Biochem Mol Biol 2011, 2: 247-256.
105. Sorrentino G, Ruggeri N, Specchia V, Cordeno nsi M, Mano M, Dupont S, Manfrin A, et al. Metabolic control of YAP and TAZ by the mevalonate pathway. Nat Cell Biol 2014, 16: 357-366.
106. Zhang W, Gao Y, Li P, Shi Z, Guo T, Li F, Han X, et al. VGLL4 functions as a new tumor suppressor in lung cancer by negatively regulating the YAP-TEAD transcriptional complex. Cell Res 2014, 24: 331-343.
107. Jiao S, Wang H , Shi Z, Dong A, Zhang W, Song X, He F, et al. A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. Cancer Cell 2014, 25: 166-180.
108. Wootten D, Christopoulos A, Sexton PM. Emerging paradigms in GPCR allostery: Implications for drug discovery. Nat Rev Drug Discov 2013, 12: 630-644.